Rates of cardiac failure during the first month of exposure to bambuterol or a cardiovascular drug studied by prescription event monitoring (PEM)
| Drug1-1-150 (ranked by rate) | No. of patients with reported cardiac failure during month 1 | No. of patient-months of exposure during month 1 | Rate (events per 1000 months of exposure) | Mean (SD) age | Males (%) |
|---|---|---|---|---|---|
| Xamoterol | 97 | 4 463 | 21.7 | 70.8 (13.9) | 53.0 |
| Nicorandil | 73 | 11 578 | 6.3 | 66.9 (11.2) | 61.1 |
| Bambuterol | 29 | 5 891 | 4.9 | 58.5 (18.6) | 44.8 |
| Losartan | 53 | 12 990 | 4.1 | 63.5 (12.1) | 40.2 |
| Diltiazem | 24 | 8 808 | 2.7 | 62.3 (13.9) | 59.3 |
| Enalapril | 33 | 13 544 | 2.4 | 61.2 (14.9) | 46.1 |
| Perindopril | 17 | 8 368 | 2.0 | 61.8 (12.7) | 45.0 |
| Nicardipine | 17 | 9 517 | 1.8 | 62.9 (13.9) | 48.4 |
| Lisinopril | 18 | 11 574 | 1.6 | 60.9 (14.3) | 44.0 |
| Ramipril | 2 | 1 277 | 1.6 | 60.5 (12.4) | 45.1 |
| Amlodipine | 12 | 12 085 | 1.0 | 61.8 (14.7) | 46.9 |
↵1-1-150 Betaxolol, doxazosin, isradipine not shown as number of patients with event was <2, or rate was <1.0 per 1000 patient-months of exposure.